The notion of incubators is catching on quickly in medical devices, thanks in part to a difficult financing climate and, in part, to the desire of some executives to find a new career path, focused on mentoring companies and leveraging skill sets across a number of projects at once. Designed primarily to get early stage product ideas to proof of principle quickly, incubators are overcoming skepticism about their proper role and beginning to make their mark on the device industry. In this two-part series, we look at several different incubator models.
by David Cassak
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.
Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.
Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.
